Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Cancer Treatment Reviews2016Vol. 45, pp. 7–18
Citations Over TimeTop 1% of 2016 papers
Thomas Eigentler, Jessica C. Hassel, Carola Berking, Jens Aberle, Oliver Bachmann, Viktor Grünwald, Katharina C. Kähler, Carmen Loquai, Niels Reinmuth, Martin Steins, Lisa Zimmer, A. Sendl, Ralf Gutzmer
Related Papers
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab(2021)13 cited
- → Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma(2017)
- → Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients(2023)
- → TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab(2024)